Prostate Cancer Clinical Trials Consortium
The OHSU Knight Cancer Institute is a member of the Prostate Cancer Clinical Trials Consortium (PCCTC), a national clinical research group sponsored by the U.S. Department of Defense. The coordinating center is at Memorial Sloan-Kettering Cancer Center . The PCCTC initiative builds on our long history of research collaboration through the Prostate Cancer Foundation. Consortium studies focus on evaluating new treatments for prostate cancer, during all prostate cancer stages.
International Blood-Brain Barrier Consortium
The International Blood-Brain Barrier (BBB) Consortium is directed from OHSU's Blood Brain Barrier Program at the OHSU Knight Cancer Institute. This program combines basic science, research and comprehensive patient care to treat patients with brain tumors. Doctors, nurses, neuropsychologists and researchers work together to meet the challenges of successfully treating people with brain tumors. They are working to develop treatments that outwit the brain's natural defense, the barrier between the bloodstream and the brain, while also protecting the brain’s function. OHSU has developed guidelines for opening the blood-brain barrier with input from the other universities in the International BBB Consortium.